Additional Information 205 Cross-reference to Form 20-F The information in this document that is referenced on this page is included in AstraZenecas Form 20-F for 2009 2009 Form 20-F and is filed with the SEC.
The 2009 Form 20-F is the only document intended to be incorporated by reference into any filings by AstraZeneca under the Securities Act of 1933, as amended.
References to major headings include all information under such major headings, including subheadings.
References to subheadings include only the information contained under such subheadings.
Graphs are not included unless specifically identified.
The 2009 Form 20-F has not been approved or disapproved by the SEC, nor has the SEC passed comment upon the accuracy or adequacy of the 2009 Form 20-F.
The 2009 Form 20-F filed with the SEC may contain modified information and may be updated from time to time.
Item Page Item Page Item Page B.
Compensation 3 Key Information 10 Additional Information Directors Report A.
Memorandum and Articles of Association Selected financial data Directors Remuneration Report 101 Financial highlights Additional Information Articles 2 204 Note 23 Post-retirement benefits 156 Group Financial Record D. Exchange controls and other limitations 193 Note 24 Employee costs and share option affecting security holders Additional Information Shareholder Information 199 plans for employees 161 Additional Information D. Risk factors Note 27 Statutory and other information 185 Exchange controls and other Directors Report limitations affecting security holders 203 C. Board practices Principal risks and uncertainties 80 E. Directors Report Taxation Board of Directors at 31 December 88 4 Information on the Company Financial Review Taxation 48 Directors Report A.
History and development of the company Additional Information Senior Executive Team at 31 December 90 Taxation for US residents 202 Additional Information History and Directors Report development of the Company 204 Additional Information Board Committee membership 93 UK and US income taxation of dividends 202 Directors Report Our resources 25, 32 Directors Report Additional Information Financial Review Investments, divestments Operation of Board Committees 94 Taxation on capital gains 202 and capital expenditure 44 Directors Report Additional Information Passive Foreign Note 7 Property, plant and equipment 139 Directors Remuneration Report 101 Investment Company PFIC rules 202 Note 22 Acquisitions of business operations 154 D. Employees Additional Information UK inheritance tax 202 B.
Business overview Directors Report People 33 Additional Information UK stamp duty Directors Report 10 reserve tax and stamp duty 203 Directors Report Our resources 25, 32 Note 6 Segment information 137 H. Note 24 Employee costs and share option Documents on display plans for employees 161 Note 1 Product revenue information 133 Additional Information Documents on display 202 Statements of competitive position, inside front E. Share ownership 11 Quantitative and Qualitative Disclosures growth rates and sales cover Directors Report about Market Risk C. Directors interests in shares 115 Organisational structure Financial Review Directors Report Directors Report Directors shareholdings 99 Financial risk management 44 Subsidiaries and principal activities 98 Additional Information Major shareholdings 200 Note 15 Financial risk management Principal Subsidiaries 186 objectives and policies 144 Note 24 Employee costs and share option plans for employees D. Property, plant and equipment 161 Note 16 Financial instruments 146 Directors Report Our resources 25, 32 7 Major Shareholders and 15 Controls and Procedures Related Party Transactions Additional Information Property 204 Directors Report Principal corporate A.
Major shareholders Note 7 Property, plant and equipment 139 governance requirements 96 Additional Information Major shareholdings 200 Directors Report Environmental Directors Report Audit Committee 94 occupational health and safety liabilities 85 B.
Related party transactions Financial Statements Directors Responsibilities for, and Report on, Internal Additional Information 5 Operating and Financial Review Control over Financial Reporting 122 and Prospects Related party transactions 201 A-F.
Note 27 Statutory and other information Directors Report 10 16 [Reserved] Related party transactions 185 Financial Review 36 A.
Audit Committee financial expert 8 Note 14 Interest-bearing loans Financial Information Directors Report Audit Committee 94 and borrowings 144 A.
Consolidated statements Directors Report Note 16 Financial instruments and other financial information 146 Board Committee membership 93 Financial Review Note 19 Capital and reserves B.
Code of ethics Retained earnings 153 Dividend and share re-purchases 42 Directors Report Code of Conduct 97 Note 25 Commitments and Directors Report Distributions to C. Principal accountant fees and services contingent liabilities 166 shareholders and dividends for 2009 98 Directors Report Audit Committee 94 Financial Statements excluding Directors 6 Directors, Senior Management responsibilities on page 122 and Auditors Note 27 Statutory and other information 185 and Employees opinion on page 123 120 E. Purchases of equity securities by the issuer A.
Directors and senior management Additional Information Shareholder Information 199 and affiliated purchasers Directors Report B.
Significant changes Note 20 Share capital of the Company Board of Directors at 31 December 88 Share re-purchases 154 Note 27 Statutory and other information 185 Directors Report G. Corporate governance Senior Executive Team at 31 December 90 9 The Offer and Listing Directors Report Principal corporate Directors Report A4.
Price history of listed stock governance requirements 96 Directors remuneration US dollars 112 Additional Information Shareholder Information 199 Directors Report Policy on external 18 Financial Statements appointments and retention of fees 110 C. Markets Financial Statements excluding Directors Additional Information Shareholder Information 199 responsibilities on page 122 and Auditors opinion on page 123 120 AstraZeneca Annual Report and Form 20-F Information 2009 AstraZeneca Annual Report and Form 20-F Information 2009
